- Home
- OPAD vs ACET Comparison
OPAD vs ACET Comparison
Compare OPAD & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- ACET
- Stock Information
- Founded
- OPAD 2015
- ACET 1947
- Country
- OPAD United States
- ACET United States
- Employees
- OPAD N/A
- ACET N/A
- Industry
- OPAD Real Estate
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- OPAD Finance
- ACET Health Care
- Exchange
- OPAD Nasdaq
- ACET Nasdaq
- Market Cap
- OPAD 39.7M
- ACET 44.4M
- IPO Year
- OPAD N/A
- ACET N/A
- Fundamental
- Price
- OPAD $1.06
- ACET $0.61
- Analyst Decision
- OPAD Hold
- ACET Buy
- Analyst Count
- OPAD 5
- ACET 6
- Target Price
- OPAD $2.38
- ACET $6.00
- AVG Volume (30 Days)
- OPAD 61.3K
- ACET 566.6K
- Earning Date
- OPAD 05-05-2025
- ACET 05-06-2025
- Dividend Yield
- OPAD N/A
- ACET N/A
- EPS Growth
- OPAD N/A
- ACET N/A
- EPS
- OPAD N/A
- ACET N/A
- Revenue
- OPAD $794,159,000.00
- ACET N/A
- Revenue This Year
- OPAD $8.29
- ACET N/A
- Revenue Next Year
- OPAD $33.17
- ACET N/A
- P/E Ratio
- OPAD N/A
- ACET N/A
- Revenue Growth
- OPAD N/A
- ACET N/A
- 52 Week Low
- OPAD $0.92
- ACET $0.45
- 52 Week High
- OPAD $7.47
- ACET $1.81
- Technical
- Relative Strength Index (RSI)
- OPAD 35.97
- ACET 48.77
- Support Level
- OPAD $0.93
- ACET $0.47
- Resistance Level
- OPAD $1.16
- ACET $0.70
- Average True Range (ATR)
- OPAD 0.14
- ACET 0.06
- MACD
- OPAD 0.01
- ACET 0.00
- Stochastic Oscillator
- OPAD 21.85
- ACET 61.84
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.